Breakthroughs in Cancer Gene Therapy: AAV Vectors Revolutionize Treatment

Strategic Insights -

Research conducted at the University of Science and Technology of China has revealed significant advancements in cancer gene therapy using adeno-associated virus (AAV) vectors. AAV vectors have been recognized as a safe and effective method for delivering therapeutic transgenes, with four AAV-based gene therapy drugs already approved by the US FDA or EMA. However, challenges such as poor packaging capacity, low organ specificity, pre-existing humoral immunity, and vector dose-dependent toxicity still exist. This review aims to address these limitations and explore potential solutions through capsid engineering, packaging capacity, and immune response optimization.

Key Takeaways:

  • AAV vectors are widely recognized as a safe and effective method for delivering therapeutic transgenes, with 4 AAV-based gene therapy drugs approved by the US FDA or EMA.
  • Despite the success of AAV vectors, challenges such as poor packaging capacity, low organ specificity, pre-existing humoral immunity, and vector dose-dependent toxicity still exist.
  • Capsid engineering, packaging capacity, and immune response optimization are critical areas of focus for improving AAV vector delivery systems.
  • Preclinical applications and clinical translation of AAV vectors hold significant promise for treating various diseases, including cancer, neurodegenerative disease, retinal disease, SARS-CoV-2, and monkeypox.
  • The review emphasizes the need for ethical and secure approaches in AAV application, particularly with the potential uses of artificial intelligence (AI), vaccines, and nanobodies.

Statistics:

  • 4 AAV-based gene therapy drugs have been approved by the US FDA or EMA.
  • AAV vectors can infect a wide variety of species, tissues, and cell types.
  • Long-lasting gene expression, low immune responses, and without host chromosome incorporation are some of the unique advantages of AAV vectors.
  • Pre-existing humoral immunity and vector dose-dependent toxicity are significant challenges in AAV vector applications.

Sources:

  • "Revolution of AAV in Drug Discovery: From Delivery System to Clinical Application" published in Journal of Medical Virology (2025;97(6))
  • VerticalNews reporting on the University of Science and Technology of China's research
  • Journal of Medical Virology (onlinelibrary.wiley.com/journal/10.1002/(ISSN)1096-9071)
  • University of Science and Technology of China, Laboratory of Structural Immunology, National Key Laboratory of Immune Response and Immunotherapy